Please login to the form below

Not currently logged in
Email:
Password:

EULAR

This page shows the latest EULAR news and features for those working in and with pharma, biotech and healthcare.

NICE approves UCB Pharma’s Cimzia

NICE approves UCB Pharma’s Cimzia

NICE insists that treatment should only continue if there is a moderate response measured using European League Against Rheumatism (EULAR) criteria at six months.

Latest news

  • GSK and J&J move closer to sirukumab filing for arthritis GSK and J&J move closer to sirukumab filing for arthritis

    Results presented at this week's Annual European Congress of Rheumatology (EULAR 2016) in London, UK, showed that sirukumab slowed down the progressive joint destruction in RA and improved the symptoms

  • NICE recommends infliximab biosimilars ahead of Remicade NICE recommends infliximab biosimilars ahead of Remicade

    And according to a position paper published by the European League Against Rheumatism (EULAR) this month, patients are also anxious about being treated with biosimilar drugs and need access to clear

  • AZ's phase III gout data frustrates firm AZ's phase III gout data frustrates firm

    The good news for AZ is that data from a phase III trial presented at the European League against Rheumatism (EULAR) meeting in Rome this week showed that lesinurad given in ... CymaBay says novel candidate promising. Meanwhile, EULAR also saw new phase

  • Patients 'sceptical' about biosimilars, says EULAR Patients 'sceptical' about biosimilars, says EULAR

    Patients 'sceptical' about biosimilars, says EULAR. Concerns for safety of drugs for arthritis and other musculoskeletal diseases. ... More than 120 million people are living with rheumatic and musculoskeletal diseases in the EU today," according to the

  • Lilly and Incyte's baricitinib aces phase III trials Lilly and Incyte's baricitinib aces phase III trials

    Top-line results from two phase III studies were reported late last year, but the data were presented in full at the ongoing EULAR meeting in Rome and show the drug

More from news
Approximately 1 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Case study: Immunology education Case study: Immunology education

    Client verdict. Sue Oliver, chair of the European League Against Rheumatism (EULAR) Healthcare Professionals Standing Committee said: “ My personal experience as Arena Chair was a rewarding and exciting one.

  • Case study: Immunology education Case study: Immunology education

    Client verdict. Sue Oliver, chair of the European League Against Rheumatism (EULAR) Healthcare Professionals Standing Committee said: “ My personal experience as Arena Chair was a rewarding and exciting one.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics